Our Company

Second Genome, a venture-backed Bay Area based life sciences company, is developing microbiome-modulating precision therapies that address significant unmet need in disease and wellness. We utilize a proprietary discovery platform to unravel the complexity of the human  microbiome and to drive advances in nutritional and pharmaceutical therapies.

In addition, we work with our global collaborators to identify novel biomarkers for classifying patient populations and to assess the impact of novel microbiome-modulating products.